1. Home
  2. SST vs COCP Comparison

SST vs COCP Comparison

Compare SST & COCP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo System1 Inc.

SST

System1 Inc.

HOLD

Current Price

$3.05

Market Cap

12.9M

ML Signal

HOLD

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

HOLD

Current Price

$0.97

Market Cap

13.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SST
COCP
Founded
2013
2006
Country
United States
United States
Employees
250
N/A
Industry
Diversified Commercial Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
13.7M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
SST
COCP
Price
$3.05
$0.97
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$6.00
AVG Volume (30 Days)
151.9K
102.9K
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
54.65
EPS
N/A
N/A
Revenue
N/A
$12,712,091.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$0.86
52 Week High
$11.30
$2.19

Technical Indicators

Market Signals
Indicator
SST
COCP
Relative Strength Index (RSI) 49.89 34.50
Support Level $3.09 $0.90
Resistance Level $3.72 $1.11
Average True Range (ATR) 0.32 0.06
MACD 0.00 -0.00
Stochastic Oscillator 33.19 15.40

Price Performance

Historical Comparison
SST
COCP

About SST System1 Inc.

System1 Inc develops technology and data science to operate a responsive acquisition marketing platform. It operate several flagship brands across multiple consumer verticals, including shopping, travel and search, and a customer acquisition and marketing platform powered by Artificial Intelligence and machine learning. The company's segment includes Marketing and Products. It generates maximum revenue from the Marketing segment. Geographically, it operates in United States and Other countries.

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.

Share on Social Networks: